STAT+: Up and down the ladder: The latest comings and goings

STAT PlusPharmalot Up and down the ladder: The latest comings and goings Manage alerts for this article Email this article Share this article By Ed SilvermanJune 12, 2026 Pharmalot Columnist, Senior Writer Ed Silverman[email protected]Ed’s stories explore prescription drug pricing, affordability and access, as well issues surrounding patents, litigation, and legislation. He is also the author of the morning Pharmalittle newsletter and the afternoon Pharmalot newsletter. Hired someone new and exciting? Promoted a rising star? Finally solved that hard-to-fill spot? Share the news with us, and we’ll share it with others. That’s right. Send us your changes, and we’ll find a home for them. Don’t be shy. Everyone wants to know who is coming and going. And here is our regular feature in which we highlight a different person each week. This time around, we note that AstronauTx hired Michelle Mellion as chief medical officer. Previously, she held the same role at PepGen and EveryONE Medicines.Advertisement But all work and no play can make for a dull chief medical officer. STAT+ Exclusive Story Already have an account? Log in This article is exclusive to STAT+ subscribers Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts. Already have an account? Log in Monthly $39 Totals $468 per year $39/month Get Started Totals $468 per year Starter $30 for 3 months, then $399/year $30 for 3 months Get Started Then $399/year Annual $399 Save 15% $399/year Get Started Save 15% 11+ Users Custom Savings start at 25%! Request A Quote Request A Quote Savings start at 25%! 2-10 Users $300 Annually per user $300/year Get Started $300 Annually per user View All Plans To read the rest of this story subscribe to STAT+. Subscribe Log In biotechnology, jobs, Pharmaceuticals, STAT+ Submit a correction requestReprints Ed Silverman Pharmalot Columnist, Senior Writer Ed’s stories explore prescription drug pricing, affordability and access, as well issues surrounding patents, litigation, and legislation. He is also the author of the morning Pharmalittle newsletter and the afternoon Pharmalot newsletter. Newsletter Understand how science, health policy, and medicine shape the world every day Recommended Pharmalot June 12, 2026 STAT Plus: Pharmalittle: We’re reading about a discontinued cancer drug, a Novo security breach, and more Pharmalot June 11, 2026 STAT Plus: Pharmalittle: We’re reading about employer coverage of obesity drugs, another Sanofi setback, and more Advertisement Pharmalot June 10, 2026 STAT Plus: Pharmalittle: We’re reading about U.S. pressure on European drug prices, longer shortages, and more Pharmalot June 9, 2026 STAT Plus: The shortage of many medicines in the U.S. remains a ‘systemic’ problem, a new analysis finds Pharmalot June 9, 2026 STAT Plus: Pharmalittle: We’re reading about a $10.6 billion GSK deal, an AstraZeneca obesity pill, and more Subscriber Picks